Severe thrombocytopenia induced by a single infusion of trastuzumab.
We report a case of severe thrombocytopenia related to adjuvant trastuzumab use. Less than 24 hours after administration of her first dose of single-agent trastuzumab, the patient was admitted to the hospital with a platelet count of 2 x 10(9)/L. Trastuzumab is being increasingly used and, to our knowledge, severe thrombocytopenia has not yet been reported as an adverse event. This case highlights a serious and potentially life-threatening complication with the use of single-agent trastuzumab.
Parikh
Omi
O
Royal Preston Hospital, London, UK. omiparikh@doctors.net.uk
Neave
Farhad
F
Palmieri
Carlo
C
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab